Reaffirmed: DaVita (NYSE:DVA) Sector Perform Rating Reconfirmed at RBC Capital; $78 Target in Place

November 9, 2018 - By Carey Conley

DaVita Inc. (NYSE:DVA) Logo

Investors sentiment decreased to 0.85 in 2018 Q2. Its down 0.05, from 0.9 in 2018Q1. It fall, as 42 investors sold DaVita Inc. shares while 156 reduced holdings. 50 funds opened positions while 119 raised stakes. 142.23 million shares or 2.37% less from 145.68 million shares in 2018Q1 were reported.

Timessquare Capital Limited Liability Com invested in 0.86% or 1.85 million shares. Denali Advsr Lc has 0.06% invested in DaVita Inc. (NYSE:DVA) for 5,900 shares. Boston Advsr Ltd Liability Company stated it has 21,776 shares. Cibc Asset Mgmt Inc has invested 0.01% of its portfolio in DaVita Inc. (NYSE:DVA). Elk Creek Prtn Limited Company has 0.02% invested in DaVita Inc. (NYSE:DVA) for 6,448 shares. First Republic Inv Mgmt owns 5,701 shares. Advisory Service Ntwk Limited Liability Co reported 97 shares. Global X Limited Co has invested 0.01% in DaVita Inc. (NYSE:DVA). Mutual Of America Cap Limited Com owns 18,015 shares. Citigroup stated it has 171,977 shares or 0.01% of all its holdings. Illinois-based Hightower Advsrs Ltd Liability Com has invested 0.01% in DaVita Inc. (NYSE:DVA). Guardian Life Insur Company Of America invested in 0% or 386 shares. Moreover, Ameriprise Financial has 0% invested in DaVita Inc. (NYSE:DVA) for 110,430 shares. Sumitomo Mitsui Asset Management Limited owns 10,819 shares. Connecticut-based Hartford Investment Mgmt Company has invested 0.03% in DaVita Inc. (NYSE:DVA).

Since May 14, 2018, it had 0 buys, and 3 selling transactions for $211,988 activity. BERG CHARLES also sold $22,393 worth of DaVita Inc. (NYSE:DVA) shares. Arway Pamela M had sold 1,264 shares worth $86,918 on Thursday, June 7.

DaVita (NYSE:DVA) Rating Reaffirmed

The financial company has just set a PT of $78 on DaVita (NYSE:DVA) shares. This is 11.19 % from the current price. In analysts report revealed to investors and clients on Thursday morning, RBC Capital reaffirmed their Sector Perform rating on shares of DVA.

DaVita Inc. (NYSE:DVA) Ratings Coverage

Among 2 analysts covering DaVita (NYSE:DVA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. DaVita had 2 analyst reports since June 6, 2018 according to SRatingsIntel. The rating was upgraded by JP Morgan on Thursday, September 13 to “Neutral”.

The stock decreased 7.79% or $5.93 during the last trading session, reaching $70.15. About 5.96M shares traded or 271.91% up from the average. DaVita Inc. (NYSE:DVA) has risen 12.06% since November 9, 2017 and is uptrending. It has underperformed by 3.56% the S&P500.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease . The company has market cap of $11.71 billion. It operates through two divisions, DaVita Kidney Care and DaVita Medical Group. It has a 23.93 P/E ratio. The firm operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.

More notable recent DaVita Inc. (NYSE:DVA) news were published by: Streetinsider.com which released: “DaVita (DVA) says it’s grateful that Californians voted down Proposition 8” on November 07, 2018, also Benzinga.com with their article: “DaVita Q3 Earnings Preview” published on November 07, 2018, Seekingalpha.com published: “APC, NBL among premarket gainers” on November 07, 2018. More interesting news about DaVita Inc. (NYSE:DVA) were released by: Seekingalpha.com and their article: “DaVita (DVA) Q3 2018 Results – Earnings Call Transcript” published on November 08, 2018 as well as Seekingalpha.com‘s news article titled: “DaVita HealthCare Partners misses by $0.32, misses on revenue” with publication date: November 07, 2018.

DaVita Inc. (NYSE:DVA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: